Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion
- Conditions
- Cystic Fibrosis
- Interventions
- Registration Number
- NCT02070744
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Brief Summary
The objective of this study was to evaluate the safety and efficacy of VX-661in combination with ivacaftor in participants with cystic fibrosis (CF) who are homozygous for F508del cystic fibrosis transmembrane conductance regulator (CFTR) mutation
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
- Homozygous for the F508del CFTR mutation
- FEV1 ≥40% and ≤90% of predicted normal for age, sex, and height
- Stable CF disease as judged by the investigator
- History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant
- Pregnant and nursing females: Females of childbearing potential must have a negative pregnancy test at screening and Day 1 of the PC Phase and Day -7 or Day 1 of the OLE Phase (whichever was applicable)
- Sexually active participants of reproductive potential who are not willing to follow the contraception requirements
- The participant or a close relative of the participant is the investigator or sub investigator, research assistant, pharmacist, study coordinator, or other staff directly involved with the conduct of the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h Ivacaftor Participants received VX-661 50 milligram (mg) tablet plus Ivacaftor (IVA) 150 mg tablet every 12 hours (q12h) for 12 weeks. PC Phase: VX 661 placebo q12h + IVA placebo q12h Placebo matched to VX-661 Participants received placebo matched to VX-661 tablet plus placebo matched to IVA tablet q12h for 12 weeks. PC Phase: VX 661 placebo q12h + IVA placebo q12h Placebo matched to Ivacaftor Participants received placebo matched to VX-661 tablet plus placebo matched to IVA tablet q12h for 12 weeks. PC Phase: VX-661 100 mg qd + IVA 150 mg q12h VX-661 Participants received two VX-661 50 mg tablets once daily (qd) plus IVA 150 mg tablet q12h for 12 weeks. PC Phase: VX -661 placebo qd + IVA placebo q12h Placebo matched to VX-661 Participants received two placebo matched to VX-661 tablets qd plus placebo matched to IVA tablet q12h for 12 weeks. PC Phase: VX -661 placebo qd + IVA placebo q12h Placebo matched to Ivacaftor Participants received two placebo matched to VX-661 tablets qd plus placebo matched to IVA tablet q12h for 12 weeks. PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h VX-661 Participants received VX-661 50 milligram (mg) tablet plus Ivacaftor (IVA) 150 mg tablet every 12 hours (q12h) for 12 weeks. OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h VX-661 Participants who completed 12 week PC phase underwent a washout period of at least 4 weeks before entering the OLE phase and received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 48 weeks in OLE phase. PC Phase: VX-661 100 mg qd + IVA 150 mg q12h Ivacaftor Participants received two VX-661 50 mg tablets once daily (qd) plus IVA 150 mg tablet q12h for 12 weeks. OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h Ivacaftor Participants who completed 12 week PC phase underwent a washout period of at least 4 weeks before entering the OLE phase and received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 48 weeks in OLE phase.
- Primary Outcome Measures
Name Time Method PC Phase: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) Baseline (PC Phase) up to 112 days AE: Any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, Inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first dose of study drug through the end of study participation considered treatment-emergent. Baseline was defined as Day 1 of PC Phase.
OLE Phase: Number of Participants With Treatment-Emergent AEs and SAEs Baseline (OLE Phase) up to 364 days AE: Any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, Inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first dose of study drug through the end of study participation considered treatment-emergent. Baseline was defined as Day 1 of the OLE Phase.
- Secondary Outcome Measures
Name Time Method PC Phase: Absolute Change From Baseline Body Mass Index (BMI) at Week 12 Baseline (PC Phase), Week 12 BMI was calculated using following formula: BMI = Weight in kg/height in square meter (m\^2). Baseline was defined as Day 1 of PC Phase.
OLE Phase: Relative Change From Baseline in Percent Predicted FEV1 Through Week 40 Baseline (OLE Phase), Through Week 40 FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of the OLE Phase.
PC Phase: Relative Change From Baseline in Percent Predicted FEV1 Through Week 12 Baseline (PC Phase), Through Week 12 FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of PC Phase.
OLE Phase: Absolute Change From Baseline BMI at Week 40 Baseline (OLE Phase), Week 40 BMI was calculated using following formula: BMI = Weight in kg/height in m\^2. Baseline was defined as Day 1 of the OLE Phase.
PC Phase: Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 12 Baseline (PC Phase), Through Week 12 The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Baseline was defined as Day 1 of PC Phase.
OLE Phase: Absolute Change From Baseline in Percent Predicted FEV1 Through Week 40 Baseline (OLE Phase), Through Week 40 FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of the OLE Phase.
PC Phase: Absolute Change From Baseline in Sweat Chloride Through Week 12 Baseline (PC Phase), Through Week 12 Sweat samples were collected using an approved collection device. Baseline was defined as Day 1 of PC Phase.
OLE Phase: Absolute Change From Baseline in Sweat Chloride Through Week 40 Baseline (OLE Phase), Through Week 40 Sweat samples were collected using an approved collection device. Baseline was defined as Day 1 of the OLE Phase.
PC Phase: Absolute Change From Baseline in Body Weight at Week 12 Baseline (PC Phase), Week 12 Baseline was defined as Day 1 of PC Phase.
OLE Phase: Absolute Change From Baseline in Body Weight at Week 40 Baseline (OLE Phase), Week 40 Baseline was defined as Day 1 of the OLE Phase.
PC Phase: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 12 Baseline (PC Phase), Through Week 12 FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of PC Phase.
OLE Phase: Absolute Change From Baseline in CFQ-R Respiratory Domain Score Through Week 40 Baseline (OLE Phase), Through Week 40 The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Baseline was defined as Day 1 of the OLE Phase.
PC Phase: Maximum Plasma Concentration (Cmax) of VX-661 and IVA Pre-dose, 2, 3, 4, 6, 9 and 12 hours post-dose on Day 85 PC Phase: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24h) of VX-661 Pre-dose, 2, 3, 4, 6, 9 and 12 hours post-dose on Day 85 Pharmacokinetic (PK) sampling was performed up to 12 hours post-dose on Day 85. For Arm VX-661 50 mg q12h + IVA 150 mg q12h (VX-661 q12h regimen), area under the concentration versus time curve from time 0 to 12 hours (AUC0-12h) was multiplied by 2 to obtain AUC0-24h.
PC Phase: Area Under the Concentration Versus Time Curve From Time 0 to 12 Hours (AUC0-12h) of IVA Pre-dose, 2, 3, 4, 6, 9 and 12 hours post-dose on Day 85 PC Phase: Time to Reach Cmax (Tmax) of VX-661 and IVA Pre-dose, 2, 3, 4, 6, 9 and 12 hours post-dose on Day 85